These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37544876)

  • 1. Not all tumour necrosis is granular necrosis: authors' response.
    Fuchs TL; Chou A; Ahadi M; Sheen A; Sioson L; Mittal A; Samra J; Gill AJ
    Pathology; 2023 Oct; 55(6):904-906. PubMed ID: 37544876
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained? Authors' reply.
    Strik AS; D'Haens GR
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1474-1475. PubMed ID: 28474830
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Authors' response.
    Turner D; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
    [No Abstract]   [Full Text] [Related]  

  • 8. Not all tumour necrosis is granular necrosis.
    Samaratunga H; Egevad L; Delahunt B
    Pathology; 2023 Oct; 55(6):903-904. PubMed ID: 37543492
    [No Abstract]   [Full Text] [Related]  

  • 9. Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha).
    McLaughlin PJ; Elwood NJ; Russell SM; Andrew SM; McKenzie IF
    Anticancer Res; 1992; 12(4):1243-6. PubMed ID: 1503416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
    Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA
    Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133
    [No Abstract]   [Full Text] [Related]  

  • 11. Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship?
    Papamichael K; Archavlis E; Lariou C; Tsigka A; Mantzaris GJ
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):857-9. PubMed ID: 22475791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of recombinant tumour necrosis factor alpha on blood flow and antibody localisation in human tumour xenografts in nude mice.
    Pimm MV; Gribben SJ; Morris TM
    J Cancer Res Clin Oncol; 1991; 117(6):543-8. PubMed ID: 1744160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease--authors' reply.
    Rosen MJ; Minar P; Vinks AA
    Aliment Pharmacol Ther; 2015 Jul; 42(2):241. PubMed ID: 26081689
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases.
    Sanchez-Hernandez JG; Rebollo N; Munoz F; Martin-Suarez A; Calvo MV
    Ann Clin Biochem; 2019 Jan; 56(1):28-41. PubMed ID: 29807436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
    Van den Bosch F; Baeten D; Kruithof E; De Keyser F; Mielants H; Veys EM
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii33-6. PubMed ID: 11890649
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model.
    Rowlinson-Busza G; Maraveyas A; Epenetos AA
    Br J Cancer; 1995 Apr; 71(4):660-5. PubMed ID: 7710925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells.
    Deem RL; Shanahan F; Targan SR
    Clin Exp Immunol; 1991 Jan; 83(1):79-84. PubMed ID: 1899066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment.
    Tsai TF
    Br J Dermatol; 2020 Jul; 183(1):7-8. PubMed ID: 32017027
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained?
    Bar-Yoseph H; Chowers Y
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1473-1474. PubMed ID: 28474829
    [No Abstract]   [Full Text] [Related]  

  • 20. Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release.
    Vossen AC; Tibbe GJ; Buurman WA; Benner R; Savelkoul HF
    Eur Cytokine Netw; 1996 Dec; 7(4):751-5. PubMed ID: 9010677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.